CareDx
CDNA
200 hedge funds and large institutions have $983M invested in CareDx in 2025 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 64 reducing their positions, and 27 closing their positions.
43,375% more call options, than puts
Call options by funds: $1.74M | Put options by funds: $4K
52% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 27
26% more capital invested
Capital invested by funds: $779M → $983M (+$204M)
7% more funds holding
Funds holding: 187 → 200 (+13)
0.77% more ownership
Funds ownership: 100.65% → 101.42% (+0.77%)
2% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 64
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
Boston Partners
Boston,
Massachusetts
|
+$14.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$7.44M |
| 3 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$5.78M |
| 4 |
Chevy Chase Trust
Bethesda,
Maryland
|
+$5.66M |
| 5 |
Jane Street
New York
|
+$5.65M |
Top Sellers
CDNA Hedge Fund Activity: Q4 2025 in Review
200 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in CareDx (CDNA) for Q4 2025, worth a combined $983M — up 26% from $779M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new CDNA positions and 27 closed out — a net gain of 14 holders — while 63 added to existing stakes and 64 trimmed.
The largest buyer was Boston Partners, adding an estimated $14.6M. The largest seller was Ophir Asset Management, cutting an estimated $21.3M.
- 200 institutional investors held CareDx (CDNA) as of Q4 2025, up from 187 in Q3 2025.
- Funds reported $983M of CareDx stock for Q4 2025, up 26% quarter-over-quarter.
- 41 funds opened new CareDx positions in Q4 2025 and 27 closed out, a net change of +14 holders.
- The largest CareDx buyer in Q4 2025 was Boston Partners, an estimated $14.6M added.
- The largest CareDx seller in Q4 2025 was Ophir Asset Management, an estimated $21.3M sold.
Based on aggregated 13F filings for Q4 2025.